Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 38.3% in July

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 58,489 shares, a decline of 38.3% from the June 30th total of 94,847 shares. Based on an average daily volume of 825,988 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Oncotelic Therapeutics Trading Down 3.8%

Oncotelic Therapeutics stock traded down $0.00 during mid-day trading on Thursday, hitting $0.04. The stock had a trading volume of 52,136 shares, compared to its average volume of 291,191. The stock has a market capitalization of $17.56 million, a PE ratio of 0.07 and a beta of -0.27. The company has a current ratio of 0.11, a quick ratio of 0.11 and a debt-to-equity ratio of 0.01. Oncotelic Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.11. The stock has a 50-day simple moving average of $0.05 and a two-hundred day simple moving average of $0.05.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.